Dolphin Vagal Nerve Stimulation for COVID-19

Health Canada Approved: Dolphin Vagal Nerve Stimulation for COVID-19

COVID 19 IS AN INFECTIOUS DISEASE

that may lead to Acute Respiratory Distress Syndrome (ARDS), characterized by widespread inflammation in the lungs, inflammatory cytokine storms, and respiratory dysfunction.

COVID-19 related acute respiratory failure – called ARDS – is now responsible for over 500,000 deaths in North America. The fight against COVID is also costly, with the Canadian Institute for Health Information recently reported ICU COVID-19 ARDS patients are costing society almost SIX times the amount of a an ICU cardiac patient. ($50,00 v s $8,400). Is there a more cost and therapeutically effective approach to this crisis?

Vagus Nerve to the Rescue

The Vagus Nerve is the 10th cranial nerve and represents 80% of your parasympathetic “brakes” within our bodies. It has been theorized in scientific literature the Vagus nerve may be beneficial in helping COVID-19 respiratory distress.

Vagal Stimulation Now Authorized by Health Canada to Treat COVID-19

Recognizing this, Health Canada has NOW approved Dolphin Vagal Nerve Stimulator (VNS) for emergency use in the acute treatment of adult patients with known or suspected COVID-19. Dolphin Vagal Stim is intended for patients experiencing asthma-related dyspnea or reduced airflow (called Acute Respiratory Distress Syndrome – ARDS) relating to COVID-19. Dolphin Vagal Nerve Stimulator (VNS) is ideal for patients where approved drug therapies are not tolerated or provide insufficient respiratory symptomatic relief, and applying non-invasive Dolphin VNS to the auricular branch of the vagus nerve (ABVN) may help COVID related respiratory distress. Dolphin VNS may be applied to COVID-10 ARDS at home or any clinical setting with minimal training